山东大学耳鼻喉眼学报 ›› 2018, Vol. 32 ›› Issue (3): 4-9.doi: 10.6040/j.issn.1673-3770.1.2018.004
李华斌, 赖玉婷
LI Huabin, LAI Yuting
摘要: 慢性鼻-鼻窦炎(CRS)是耳鼻咽喉头颈外科的多因素疾病。根据患者症状、鼻内镜检查以及鼻窦CT扫描,CRS的诊断比较明确,但其病理机制却较复杂,治疗方式的选择也不完全一样。临床上应该更多地考虑内在的病理机制类型,采取针对性的治疗方式,以达到最好的治疗效果。
中图分类号:
| [1] Fokkens WJ, Lund VJ, Mullol J, et al. European position paper on rhinosinusitis and nasal polyps 2012[J]. Rhinol Suppl, 2012, 23:3 p preceding table of contents, 1-298. [2] Kato A. Immunopathology of chronic rhinosinusitis[J]. Allergol Int, 2015, 64(2):121-130. [3] Steinke JW, Borish L. Chronic rhinosinusitis phenotypes[J]. Ann Allergy Asthma Immunol, 2016, 117(3):234-240. [4] Cho SW, Kim DW, Kim JW, et al. Classification of chronic rhinosinusitis according to a nasal polyp and tissue eosinophilia: limitation of current classification system for Asian population[J]. Asia Pac Allergy, 2017, 7(3):121-130. [5] Wang X, Zhang N, Bo M, et al. Diversity of TH cytokine profiles in patients with chronic rhinosinusitis: a multicenter study in europe, asia, and oceania[J]. J Allergy Clin Immunol, 2016, 138(5):1344-1353. [6] Maxfield AZ, Landegger LD, Brook CD, et al. Periostin as a biomarker for nasal polyps in chronic rhinosinusitis[J]. Otolaryngol Head Neck Surg, 2018, 158(1):181-186. [7] Jonstam K, Westman M, Holtappels G, et al. Serum periostin, ige, and se-ige can be used as biomarkers to identify moderate to severe chronic rhinosinusitis with nasal polyps[J]. J Allergy Clin Immun, 2017, 140(6):1705-1708. [8] Van Zele T, Claeys S, Gevaert P, et al. Differentiation of chronic sinus diseases by measurement of inflammatory mediators[J]. Allergy, 2006, 61(11):1280-1289. [9] Van Crombruggen K, Zhang N, Gevaert P, et al. Pathogenesis of chronic rhinosinusitis: inflammation[J]. J Allergy Clin Immunol, 2011, 128(4):728-732. [10] Payne SC, Early SB, Huyett P, et al. Evidence for distinct histologic profile of nasal polyps with and without eosinophilia[J]. Laryngoscope, 2011, 121(10):2262-2267. [11] Van Bruaene N, Derycke L, Perez-Novo CA, et al. Tgf-beta signaling and collagen deposition in chronic rhinosinusitis[J]. J Allergy Clin Immunol, 2009, 124(2):253-259. [12] Takabayashi T, Kato A, Peters AT, et al. Excessive fibrin deposition in nasal polyps caused by fibrinolytic impairment through reduction of tissue plasminogen activator expression[J]. Am J Respir Crit Care Med, 2013, 187(1):49-57. [13] Kato A. Immunopathology of chronic rhinosinusitis[J]. Allergol Int, 2015, 64(2):121-130. [14] Klimek L, Koennecke M, Mullol J, et al. A possible role of stem cells in nasal polyposis[J]. Allergy, 2017, 72(12):1868-1873. [15] Yu XM, Li CW, Chao SS, et al. Reduced growth and proliferation dynamics of nasal epithelial stem/progenitor cells in nasal polyps in vitro[J]. Sci Rep, 2014, 4:4619. DOI:10.1038/srep04619. [16] Pezato R, de Almeida DC, Bezerra TF, et al. Immunoregulatory effects of bone marrow-derived mesenchymal stem cells in the nasal polyp microenvironment[J]. Mediators Inflamm, 2014, 2014:583409. DOI:10.1155/2014/583409. [17] Cho KS, Kim YW, Kang MJ, et al. Immunomodulatory effect of mesenchymal stem cells on T lymphocyte and cytokine expression in nasal polyps[J]. Otolaryngol Head Neck Surg, 2014, 150(6):1062-1070. [18] Ho J, Bailey M, Zaunders J, et al. Group 2 innate lymphoid cells(ilc2s)are increased in chronic rhinosinusitis with nasal polyps or eosinophilia[J]. Clin Exp Allergy, 2015, 45(2):394-403. [19] Lam M, Hull L, Imrie A, et al. Interleukin-25 and interleukin-33 as mediators of eosinophilic inflammation in chronic rhinosinusitis[J]. Am J Rhinol Allergy, 2015, 29(3):175-181. [20] Shin HW, Kim DK, Park MH, et al. Il-25 as a novel therapeutic target in nasal polyps of patients with chronic rhinosinusitis[J]. J Allergy Clin Immunol, 2015, 135(6):1476-1485. [21] Bachert C, Gevaert E. Advances in rhinitis and rhinosinusitis in 2015[J]. J Allergy Clin Immunol, 2016, 138(5):1277-1283. [22] Mullol J, Obando A, Pujols L, et al. Corticosteroid treatment in chronic rhinosinusitis: the possibilities and the limits[J]. Immunol Allergy Clin North Am, 2009, 29(4):657-668. [23] Schlosser RJ, Bolger WE. Nasal cerebrospinal fluid leaks: chritical review and surgical considerations[J]. Laryngoscope, 2004, 114(2):255-265. [24] Koay B, Bates G, Elston J. Endoscopic orbital decompression for dysthyroid eye disease[J]. J Laryngol Otol, 1997, 111(10):946-949. [25] Wigand ME, Hosemann WG. Results of endoscopic surgery of the paranasal sinuses and anterior skull base[J]. J Otolaryngol, 1991, 20(6):385-390. [26] Bachert C, Akdis CA. Phenotypes and emerging endotypes of chronic rhinosinusitis[J]. J Allergy Clin Immunol Pract, 2016, 4(4):621-628. [27] Stevens WW, Ocampo CJ, Berdnikovs S, et al. Cytokines in chronic rhinosinusitis role in eosinophilia and aspirin-exacerbated respiratory disease[J]. Am J Respir Crit Care Med, 2015, 192(6):682-694. [28] Yoo F, Ference EH, Kuan EC, et al. Evaluation of patient nasal saline irrigation practices following endoscopic sinus surgery[J]. Int Forum Allergy Rhinol, 2018, 8(1):32-40. [29] Rezaeian A. Outcome of spray cryotherapy plus functional endoscopic sinus surgery on management of healing in nasal polyposis[J] Am J Otolaryngol, 2018, 39(1):10-13. [30] Chen JN, Wang X, Chen LZ, et al. Influence of hyaluronan nasal dressing on clinical outcome after endoscopic sinus surgery: a systematic review and meta-analysis[J]. Am J Rhinol Allergy, 2017, 31(4):256-259. [31] Lou H, Meng Y, Piao Y, et al. Predictive significance of tissue eosinophilia for nasal polyp recurrence in the chinese population[J]. Am J Rhinol Allergy, 2015, 29(5):350-356. [32] Van Zele T, Holtappels G, Gevaert P, et al. Differences in initial immunoprofiles between recurrent and nonrecurrent chronic rhinosinusitis with nasal polyps[J]. Am J Rhinol Allergy, 2014, 28(3):192-198. [33] Ramakrishnan VR, Hauser LJ, Feazel LM, et al. Sinus microbiota varies among chronic rhinosinusitis phenotypes and predicts surgical outcome[J]. J Allergy Clin Immunol, 2015, 136(2):334-342. [34] Kennedy JL, Hubbard MA, Huyett P, et al. Sino-nasal outcome test(snot-22): a predictor of postsurgical improvement in patients with chronic sinusitis[J]. Ann Allergy Asthma Immunol, 2013, 111(4):246-251. [35] Dautremont JF, Rudmik L. When are we operating for chronic rhinosinusitis? A systematic review of maximal medical therapy protocols prior to endoscopic sinus surgery[J]. Int Forum Allergy Rhinol, 2015, 5(12):1095-1103. [36] Sylvester DC, Carr S, Nix P. Maximal medical therapy for chronic rhinosinusitis: a survey of otolaryngology consultants in the united kingdom[J]. Int Forum Allergy Rhinol, 2013, 3(2):129-132. [37] Schwartz JS, Tajudeen BA, Cohen NA. Medical management of chronic rhinosinusitis-an update[J]. Expert Rev Clin Pharmacol, 2016, 9(5):695-704. [38] Orlandi RR, Kingdom TT, Hwang PH, et al. International consensus statement on allergy and rhinology: rhinosinusitis[J]. Int Forum Allergy Rhinol, 2016, 6(Suppl 1):22-209. DOI:10.1002/air.21695. [39] Chong LY, Head K, Hopkins C, et al. Intranasal steroids versus placebo or no intervention for chronic rhinosinusitis[J]. Cochrane Database Syst Rev, 2016, 4. DOI: 10. 1002/14651858. [40] Head K, Chong LY, Hopkins C, et al. Short-course oral steroids alone for chronic rhinosinusitis[J]. Cochrane Database Syst Rev, 2016, 4. DOI: 10. 1002/14651858. [41] Poetker DM, Reh DD. A comprehensive review of the adverse effects of systemic corticosteroids[J]. Otolaryngol Clin North Am, 2010, 43(4):753-768. [42] Soler ZM, Oyer SL, Kern RC, et al. Antimicrobials and chronic rhinosinusitis with or without polyposis in adults: an evidenced-based review with recommendations[J]. Int Forum Allergy Rhinol, 2013, 3(1):31-47. [43] Oakley GM, Harvey RJ, Lund VJ. The role of macrolides in chronic rhinosinusitis(crssnp and crswnp)[J]. Curr Allergy Asthma Rep, 2017, 17(5):30. [44] Lee JT, Chiu AG. Topical anti-infective sinonasal irrigations: update and literature review[J]. Am J Rhinol Allergy, 2014, 28(1):29-38. [45] Bachert C, Mannent L, Naclerio RM, et al. Effect of subcutaneous dupilumab on nasal polyp burden in patients with chronic sinusitis and nasal polyposis:a randomized clinical trial[J]. JAMA, 2016, 315(5):469-479. [46] Gevaert P, Calus L, Van Zele T, et al. Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma[J]. J Allergy Clin Immunol, 2013, 131(1):110-116. [47] Gevaert P, Lang-Loidolt D, Lackner A, et al. Nasal il-5 levels determine the response to anti-il-5 treatment in patients with nasal polyps[J]. J Allergy Clin Immunol, 2006, 118(5):1133-1141. [48] Sivasubramaniam R, Harvey RJ. How to assess, control, and manage uncontrolled crs/nasal polyp patients[J]. Curr Allergy Asthma Rep, 2017, 17(9):58. |
| [1] | 李梦欣,徐慧,张晓玲,薛晴,纪霜钰,李莹莹,崔丽梅,郭兆剑,宋西成,孙岩,陈良. 糖皮质激素通过下调水通道蛋白2缓解精氨酸加压素诱导的膜迷路积水[J]. 山东大学耳鼻喉眼学报, 2026, 40(3): 1-6. |
| [2] | 冯思聪,于晓岚,娄丹. 基于囊泡组织Ki67、GM-CSF表达评估Messerklinger中鼻甲成形术对慢性鼻-鼻窦炎合并鼻息肉的效果[J]. 山东大学耳鼻喉眼学报, 2026, 40(3): 31-39. |
| [3] | 翟雪纯,边欣,陈敬彩,邓家钰,叶子,杨萍丽. 慢性额窦炎患者焦虑抑郁特点及横断面研究[J]. 山东大学耳鼻喉眼学报, 2026, 40(2): 35-43. |
| [4] | 吉睿,刘雅洁,王佳琪,史雅文,张炜明,殷敏. 慢性间歇性缺氧对大鼠茎突舌肌的影响及作用机制[J]. 山东大学耳鼻喉眼学报, 2026, 40(2): 44-48. |
| [5] | 段思妤,薛金梅. 组蛋白去乙酰化酶2在慢性气道炎症性疾病糖皮质激素抵抗中的研究进展[J]. 山东大学耳鼻喉眼学报, 2026, 40(1): 120-126. |
| [6] | 刘一洁,卢秀珍,吴秋欣. 外泌体在眼病发病机制和诊疗中的研究进展[J]. 山东大学耳鼻喉眼学报, 2026, 40(1): 135-141. |
| [7] | 李阳松,袁发洋,杨艳,张田,喻国冻. 基于Web of Science进行生物制剂治疗慢性鼻窦炎文献计量学分析[J]. 山东大学耳鼻喉眼学报, 2025, 39(6): 54-64. |
| [8] | 杜康丽,郑振宇,徐战将,张宇,陈露,卢梦垚. 鼻中隔偏曲并发慢性鼻窦炎风险预测模型的构建与验证[J]. 山东大学耳鼻喉眼学报, 2025, 39(6): 78-86. |
| [9] | 熊琴, 张砚, 乌日娜, 李锋, 唐力行. 鼻用糖皮质激素在儿童中的应用[J]. 山东大学耳鼻喉眼学报, 2025, 39(6): 160-167. |
| [10] | 张家齐,袁野,洪陈,顾敏,程雷,陆美萍. 基于孟德尔随机化的肠道菌群与慢性鼻窦炎鼻息肉的因果关系及代谢物中介研究[J]. 山东大学耳鼻喉眼学报, 2025, 39(5): 49-60. |
| [11] | 董雪林,张治军. 掩蔽声治疗慢性主观性耳鸣的焦虑抑郁状态分析[J]. 山东大学耳鼻喉眼学报, 2025, 39(2): 18-24. |
| [12] | 张广玲,陈兴雪,武天义,孙占伟,王卫卫,李世超,王广科. Tespa1在慢性鼻窦炎伴鼻息肉中的表达及作用研究[J]. 山东大学耳鼻喉眼学报, 2025, 39(2): 35-42. |
| [13] | 曹正勇,李小波. 慢性鼻-鼻窦炎合并哮喘术后短程局部使用糖皮质激素辅助治疗的安全性和有效性[J]. 山东大学耳鼻喉眼学报, 2025, 39(2): 43-50. |
| [14] | 潘佳煜,张春林. 急性低频感音神经性听力下降病因及发病机制的研究进展[J]. 山东大学耳鼻喉眼学报, 2025, 39(2): 126-131. |
| [15] | 周荷青,申琪. 中医药治疗变应性鼻炎疗效的生物标志物研究进展[J]. 山东大学耳鼻喉眼学报, 2025, 39(2): 168-176. |
|
||